Estimated Control Closed Transaction verified biopharmaceuticalsBiotechfood allergy therapeuticspeanut allergy therapyTherapeutics
Aimmune Therapeutics acquired by Sociétés des Produits Nestlé S.A. / Nestlé Health Science
Sociétés des Produits Nestlé S.A. / Nestlé Health Science acquired Aimmune Therapeutics, a US therapeutics brand, on Oct 13, 2020.
Transaction summary
- Target
- Aimmune Therapeutics
- Seller
- -
- Announced
- 2020-08-31
- Geography
- United States
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-08-08
- Latest update
- 2026-08-08
Value and multiples
100% enterprise value
USD 2.6B
100% enterprise value | USD
Basis: Public source
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- Nestle first-party releases support the $2.6bn headline value and 13 October 2020 completion. No transaction EBITDA or defensible EBITDA multiple is retained.
Source summary
No public source summary has been published for this transaction yet.
Continue your research
Related transaction comps
Biotech
Edgewise Therapeutics' Muscular Dystrophy Business acquired by Servier
2026-07-13 · Confirmed
View transaction → BiotechTubulis acquired by Gilead Sciences
2026-05-21 · Confirmed
View transaction → BiotechAtaiBeckley acquired by Eli Lilly and Company
- · Confirmed
View transaction → TherapeuticsDersimelagon rights acquired by LEO Pharma
2026-08-18 · Confirmed
View transaction →